<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Primary cutaneous anaplastic large cell lymphoma
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Primary cutaneous anaplastic large cell lymphoma
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Primary cutaneous anaplastic large cell lymphoma
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Eric Jacobsen, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Timothy M Kuzel, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alan G Rosmarin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 11, 2021.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H2766877647">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Primary cutaneous T cell lymphoma (PCTL) refers to cases of T cell lymphoma that present in the skin where there is no evidence of systemic (extracutaneous) disease at the time of diagnosis and after the completion of an initial staging evaluation.
        </p>
        <p>
         Primary cutaneous CD30-positive T cell lymphoproliferative disorders are the second most common category of cutaneous T cell lymphoma in the World Health Organization (WHO) classification of lymphoid neoplasms [
         <a href="#rid1">
          1
         </a>
         ]. This is a spectrum of disorders that ranges from the more benign lymphomatoid papulosis (which almost always regresses spontaneously) to the neoplastic primary cutaneous anaplastic large cell lymphoma (PC-ALCL), and includes "borderline" cases with features of each.
        </p>
        <p>
         This topic will focus on the diagnosis and management of PC-ALCL. The diagnosis and management of systemic ALCL and lymphomatoid papulosis are presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/99237.html" rel="external">
          "Initial treatment of systemic anaplastic large cell lymphoma (sALCL)"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/15725.html" rel="external">
          "Lymphomatoid papulosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H544497575">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         PC-ALCL is rare and the exact incidence is not known partially because it is difficult to distinguish cases of PC-ALCL within the larger group of CD30-positive cutaneous lymphoproliferative disorders (ie, lymphomatoid papulosis and borderline cases). In an analysis of the Surveillance, Epidemiology, and End Results (SEER) database, 157 cases of primary, localized CD30-positive cutaneous lymphoproliferative disorder were documented over a 30-year timespan [
         <a href="#rid2">
          2
         </a>
         ]. The median age at diagnosis was 61 years (range 5 to 98 years). There was a slight male predominance (58 percent) and most cases were diagnosed in White individuals (87 percent). Other epidemiologic reports have had similar findings [
         <a href="#rid3">
          3,4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3177676750">
         <span class="h1">
          CLINICAL AND PATHOLOGIC FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with PC-ALCL present with solitary or grouped nodules growing over weeks to months and measuring up to several centimeters. These nodules typically ulcerate with time  (
         <a class="graphic graphic_picture graphicRef83089" href="/z/d/graphic/83089.html" rel="external">
          picture 1
         </a>
         ). The lesions regress in up to 50 percent of cases but rarely completely resolve [
         <a href="#rid5">
          5
         </a>
         ]. Multifocal disease is rare at the time of diagnosis  (
         <a class="graphic graphic_picture graphicRef83091" href="/z/d/graphic/83091.html" rel="external">
          picture 2
         </a>
         and
         <a class="graphic graphic_picture graphicRef83092" href="/z/d/graphic/83092.html" rel="external">
          picture 3
         </a>
         ) and extracutaneous spread occurs in up to 13 percent of cases, at the time of relapse [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         Skin biopsy specimens are characterized by a dense dermal infiltrate that does not usually involve the epidermis [
         <a href="#rid7">
          7,8
         </a>
         ]. The infiltrate is comprised of cohesive sheets of large CD30-positive tumor cells that morphologically resemble those of systemic ALCL (ie, large cells with abundant pale, eosinophilic cytoplasm and round or pleomorphic, often horseshoe-shaped nuclei with prominent nucleoli). Approximately one-quarter have an atypical, non-anaplastic appearance. Reactive lymphocytes, histiocytes, eosinophils, and neutrophils are commonly present in the periphery of the lesion and in ulcerating lesions in association with epidermal hyperplasia. (See
         <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)", section on 'Classical variant'
         </a>
         .)
        </p>
        <p>
         By definition, at least 75 percent of the tumor cells express CD30 [
         <a href="#rid7">
          7-9
         </a>
         ]. In addition, most cases express CD4 and have variable loss of CD2, CD3, and CD5. Most cases are positive for cutaneous lymphocyte antigen (CLA, HECA-452), but unlike systemic ALCL, they lack expression of epithelial membrane antigen (EMA) and anaplastic lymphoma kinase (ALK). (See
         <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)", section on 'Immunophenotype'
         </a>
         .)
        </p>
        <p>
         Most cases show clonal rearrangement of the T cell receptor (
         <em>
          TCR
         </em>
         ) genes, although TCR proteins are often not expressed [
         <a href="#rid7">
          7,8
         </a>
         ]. Unlike systemic ALCL, PC-ALCL do not have gene rearrangements involving the
         <em>
          ALK
         </em>
         gene on chromosome 2p23 [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2257773564">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The diagnosis of PC-ALCL requires a representative biopsy. Excisional biopsies are preferred to incisional biopsies. If a punch biopsy is taken, the diameter should be at least 4 millimeters. The biopsy specimen is evaluated for morphology, growth pattern, and immunohistochemical studies. The diagnosis is based upon the presence of characteristic findings on biopsy specimens in conjunction with the clinical features found on presentation. (See
         <a class="local">
          'Clinical and pathologic features'
         </a>
         above.)
        </p>
        <p>
         All patients with a presumed diagnosis of PC-ALCL should undergo a staging assessment to confirm the absence of systemic disease. This evaluation includes a physical examination, complete blood count with differential, and radiographic staging [
         <a href="#rid8">
          8,11
         </a>
         ]. For imaging, we prefer a contrast-enhanced computed tomography scan combined with positron emission tomography (PET/CT), but a CT of the chest, abdomen, and pelvis is acceptable if PET is not available. The utility of a bone marrow biopsy and aspirate in the absence of clinically or radiographically detectable disseminated disease remains debatable, but we do suggest it. Others reserve bone marrow examination for patients with multifocal tumors, unexplained cytopenias, and those with documented extracutaneous disease [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
         A clinical or radiographic suspicion of disseminated disease should be confirmed by biopsy since local or regional nodes may be abnormal due to inflammation alone. Of importance, the presence of pathologic involvement of local nodes alone does not seem to portend an adverse prognosis in patients with PC-ALCL [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3535904525">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with PC-ALCL present with solitary or grouped slowly enlarging nodules that demonstrate a CD30-positive lymphoid infiltrate on biopsy. The main entities that should be considered in the differential diagnosis are lymphomatoid papulosis, systemic ALCL, transformed mycosis fungoides, and reactive causes of CD30-positive lymphoid infiltrates.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Lymphomatoid papulosis (LyP)
         </strong>
         – LyP is a recurrent, self-healing condition characterized by a papulonodular skin eruption with histologic features of a CD30-positive lymphoid proliferation of atypical T cells. In contrast to PC-ALCL, LyP lesions are usually smaller (&lt;2 cm) and resolve spontaneously after weeks to months, often leaving residual scars and hyperpigmentation [
         <a href="#rid7">
          7,8,12
         </a>
         ]. There is considerable clinical, histologic, and immunophenotypic overlap between LyP and PC-ALCL. A waxing and waning clinical course is consistent with LyP. Skin lesions that do not spontaneously regress within eight weeks are suggestive of PC-ALCL. The term "borderline" is used for cases in which a distinction between PC-ALCL and LyP cannot be made despite careful clinical and pathologic evaluation [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/15725.html" rel="external">
          "Lymphomatoid papulosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transformed mycosis fungoides
         </strong>
         – About half of transformed mycosis fungoides and Sézary syndrome express CD30. A previous history of patch or plaque mycosis fungoides or erythroderma is suggestive of the diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16193.html" rel="external">
          "Clinical presentation, pathologic features, and diagnosis of Sézary syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Systemic lymphoma
         </strong>
         – As described above, all patients with a presumed diagnosis of PC-ALCL should undergo a staging assessment to confirm the absence of systemic disease. Involvement of regional lymph nodes does not necessarily indicate the presence of systemic disease as pathologic involvement of local nodes alone does not impact the prognosis in patients with PC-ALCL [
         <a href="#rid4">
          4
         </a>
         ]. In patients with cutaneous lesions suggestive of PC-ALCL, expression of ALK or identification of a translocation involving ALK is highly suggestive of cutaneous involvement of systemic ALCL rather than PC-ALCL. (See
         <a class="medical medical_review" href="/z/d/html/4705.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of systemic anaplastic large cell lymphoma (sALCL)", section on 'Immunophenotype'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Adult T cell leukemia-lymphoma (ATLL) can present with cutaneous lesions that may be difficult to distinguish from PC-ALCL. The cells can be anaplastic in appearance, express CD30, and are ALK negative. ATLL is caused by the human retrovirus HTLV-1 and the key distinguishing feature is the presence of HTLV-1 in the malignant cells of ATL. (See
         <a class="medical medical_review" href="/z/d/html/4697.html" rel="external">
          "Clinical manifestations, pathologic features, and diagnosis of adult T cell leukemia-lymphoma"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hodgkin lymphoma (HL) expresses CD30 and rarely presents with cutaneous involvement. Unlike PC-ALCL, HL expresses CD15. (See
         <a class="medical medical_review" href="/z/d/html/4691.html" rel="external">
          "Hodgkin lymphoma: Epidemiology and risk factors"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Reactive lymphoid hyperplasia
         </strong>
         – CD30-positive lymphoid infiltrates may develop in response to insect bites or infestations (eg, scabies), viral infections (eg, herpes simplex, varicella-zoster), and certain medications (eg, anticonvulsant medications) [
         <a href="#rid12">
          12
         </a>
         ]. These non-neoplastic causes are usually associated with a lower percentage of CD30-positive cells on biopsy, do not have a waxing and waning clinical course, and do not show T cell receptor (TCR
         <em>
          )
         </em>
         gene rearrangement on molecular genetic studies. (See
         <a class="medical medical_review" href="/z/d/html/15725.html" rel="external">
          "Lymphomatoid papulosis", section on 'CD30+ inflammatory and infectious diseases'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3486491931">
         <span class="h1">
          TREATMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The key to the management of patients with PC-ALCL is to avoid overtreatment. Oncologists unfamiliar with the disease may recommend aggressive systemic chemotherapy including high-dose chemotherapy and autologous hematopoietic cell transplantation when such steps are unnecessary and overly toxic. (See
         <a class="local">
          'Choice of agent'
         </a>
         below.)
        </p>
        <p>
         Most data regarding management of recurrent, multifocal, or systemic PC-ALCL come from small cohort series, case reports, and small single-center trials. Interpretation of the available evidence is further complicated by the fact that patients with relapsing disease are treated with several therapies concurrently, thereby limiting assessment of the efficacy of individual modalities.
        </p>
        <p class="headingAnchor" id="H1309753570">
         <span class="h2">
          Initial management
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with PC-ALCL present with isolated lesions that can be managed with complete surgical excision (with negative margins) or radiation. Using this approach, the majority of patients will achieve a complete remission, although most will recur and require subsequent therapy.
        </p>
        <p>
         For patients with solitary lesions without lymph node involvement, either of these modalities is acceptable. A choice is often made based on the location of the lesions and expertise available at the treatment center. For patients with pathologically confirmed, isolated involvement of local nodes, we suggest radiation to the primary lesion and the local node(s) rather than surgical excision alone or systemic therapy. In this setting, regional lymph node involvement does not appear to impart an adverse prognosis.
        </p>
        <p>
         A retrospective cohort analysis evaluated the efficacy of surgical excision with or without radiation in 56 patients with CD30-positive cutaneous lymphoproliferative disorders [
         <a href="#rid6">
          6
         </a>
         ]. Among those with solitary PC-ALCL treated with surgical excision, 95 percent achieved a complete response and 41 percent recurred within a follow-up period of 22 months. Among those treated with surgery plus radiation, 64 percent recurred during a follow-up period of 55 months. This was not a randomized trial and the patient populations likely differ between the two groups. Even so, these results suggest that there is no compelling evidence that adding radiotherapy to complete surgical excision benefits patients with localized disease.
        </p>
        <p>
         The optimal dose of radiation for PC-ALCL is not known. Electrons are frequently used with a dose of 36 to 40 Gy and a margin of at least 2 cm, though lower doses may be equally efficacious [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3624865569">
         <span class="h2">
          Recurrent disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         While the vast majority of patients will attain a complete remission following initial therapy, most will recur within the first five years. The management of recurrent disease is largely dependent on the extent of disease. However, many patients will experience serial relapses and will be treated with each of the therapies described at some point during their disease course. A preferred order for their use has not been established. A choice is made based on the patient's prior treatment, the therapies' expected toxicities, and comorbid illnesses.
        </p>
        <p class="headingAnchor" id="H767815173">
         <span class="h3">
          Localized lesions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cutaneous recurrences after primary surgery or radiation can be treated with the same modalities again, although multiple surgeries and/or multiple radiation treatments often induce morbidity or patient inconvenience over time. Given the tendency for spontaneous regression, recurrent lesions can be observed if they are not bothersome to the patient.
        </p>
        <p>
         Patients who experience multiple recurrences for whom repeated surgical excision and/or radiation could become excessively morbid are typically better served by systemic therapy. (See
         <a class="local">
          'Multiple lesions'
         </a>
         below.)
        </p>
        <p>
         Case reports and small case series have described the use of topical therapies such as the immune response modifier
         <a class="drug drug_general" data-topicid="8638" href="/z/d/drug information/8638.html" rel="external">
          imiquimod
         </a>
         [
         <a href="#rid14">
          14
         </a>
         ], intralesional interferon alfa [
         <a href="#rid15">
          15
         </a>
         ], and topical
         <a class="drug drug_general" data-topicid="8695" href="/z/d/drug information/8695.html" rel="external">
          bexarotene
         </a>
         gel [
         <a href="#rid16">
          16,17
         </a>
         ]. Topical bexarotene can cause an intense localized retinoid dermatitis that often necessitates concomitant administration of topical corticosteroids. Patients on any of these therapies should be followed in conjunction with a dermatologist experienced with their use.
        </p>
        <p class="headingAnchor" id="H1513033771">
         <span class="h3">
          Multiple lesions
         </span>
        </p>
        <p class="headingAnchor" id="H2787834435">
         <span class="h4">
          Choice of agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         We offer systemic therapy to patients with more widespread disease, and to those who experience multiple recurrences for whom repeated surgical excision and/or radiation could become excessively morbid.
        </p>
        <p>
         The choice of systemic therapy is influenced by prior therapies, likely toxicities, comorbid illnesses, physician experience, and patient preferences. We offer the following approach:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Oral
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         is our preferred initial systemic therapy given its reasonable response rate, convenience, and favorable toxicity profile. (See
         <a class="local">
          'Oral methotrexate'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients who have a contraindication to
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         , acceptable alternatives include oral
         <a class="drug drug_general" data-topicid="8695" href="/z/d/drug information/8695.html" rel="external">
          bexarotene
         </a>
         or single agent chemotherapy. Interferon may also be used in this population, although it is often difficult to tolerate given its toxicities.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="16806" href="/z/d/drug information/16806.html" rel="external">
          Brentuximab vedotin
         </a>
         (BV) is another option for patients who received prior radiation therapy. (See
         <a class="local">
          'Brentuximab vedotin'
         </a>
         below and
         <a class="local">
          'Bexarotene'
         </a>
         below and
         <a class="local">
          'Other agents'
         </a>
         below and
         <a class="local">
          'Interferon'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We favor BV for patients who progressed on or are intolerant of initial systemic therapy. (See
         <a class="local">
          'Brentuximab vedotin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients in whom BV is ineffective or causes unacceptable toxicity, we offer sequential single agent therapy with
         <a class="drug drug_general" data-topicid="9536" href="/z/d/drug information/9536.html" rel="external">
          romidepsin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9530" href="/z/d/drug information/9530.html" rel="external">
          pralatrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         , or liposomal
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         , as used in mycosis fungoides. (See
         <a class="local">
          'Widespread nodal or visceral involvement'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Although most data regarding these agents in PC-ALCL come from small cohort series, case reports, and small single-center trials, one randomized trial demonstrated superior efficacy (but increased peripheral neuropathy) for patients assigned to BV compared with physician's choice of
         <a class="drug drug_general" data-topicid="8695" href="/z/d/drug information/8695.html" rel="external">
          bexarotene
         </a>
         or
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         [
         <a href="#rid18">
          18
         </a>
         ]. (See
         <a class="local">
          'Brentuximab vedotin'
         </a>
         below.)
        </p>
        <p>
         In contrast, multiagent chemotherapy, such as CHOP (
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ), has not proven superior to these less aggressive strategies. We reserve multiagent chemotherapy for patients with widespread nodal or visceral involvement or patients who have failed numerous single agents and skin-directed therapy. (See
         <a class="local">
          'Widespread nodal or visceral involvement'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2905322405">
         <span class="h4">
          Oral methotrexate
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         is our preferred initial systemic therapy. In one study, 10 of 13 (77 percent) patients with PC-ALCL responded to oral methotrexate [
         <a href="#rid19">
          19
         </a>
         ]. Most of these patients responded within four weeks, and the median duration of methotrexate treatment was 39 months.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing
         </strong>
         – A typical starting dose for
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         is 15 mg in two divided doses once per week (ie, 7.5 mg orally twice per day on a chosen day of the week). We have patients take
         <a class="drug drug_general" data-topicid="8475" href="/z/d/drug information/8475.html" rel="external">
          folic acid
         </a>
         1 mg daily on the days they are not taking methotrexate. Proton-pump inhibitors can increase methotrexate levels and should be used with caution in this population.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         dose can be titrated up (or down) based upon efficacy or tolerance, but we do not typically use doses higher than 25 mg weekly. Dose adjustments should be made if there is no clinical improvement within eight weeks of therapy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Duration of therapy
         </strong>
         – Although the optimal duration of treatment is unclear, we tend to treat to best response and then decrease the frequency of
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         and continue as maintenance therapy for a maximum of three years. In our experience, even once monthly dosing can be effective to maintain remissions. We limit maintenance to three years because 50 percent of patients treated with methotrexate for three years had evidence of hepatic fibrosis in one series [
         <a href="#rid19">
          19
         </a>
         ]. Methotrexate can be reinstituted if there is evidence of recurrence.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Contraindications and adverse effects
         </strong>
         – Important contraindications to
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         therapy include liver disease, renal disease, and pregnancy or planned pregnancy (for both women and men). Before initiating long-term methotrexate therapy, screening for hepatitis B and hepatitis C virus infection is recommended. In patients with infection, this allows a decision whether to avoid the use of methotrexate, to try to eradicate the viral infection before initiating therapy, or to suppress viral replication during immunosuppressive therapy. Patients receiving low-dose methotrexate should have periodic monitoring of peripheral blood counts, aminotransaminases, and albumin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Minor adverse effects, including nausea, stomach upset, headache, and fatigue, occur in most patients treated with low-dose
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         . Hepatotoxicity, pulmonary fibrosis, and myelosuppression are serious adverse effects of methotrexate treatment and may infrequently occur with low-dose therapy. (See
         <a class="medical medical_review" href="/z/d/html/7509.html" rel="external">
          "Major side effects of low-dose methotrexate"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2650003277">
         <span class="h4">
          Bexarotene
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8695" href="/z/d/drug information/8695.html" rel="external">
          Bexarotene
         </a>
         is a systemic rexinoid (synthetic agent that binds to the retinoid "X" receptor) that is widely used in mycosis fungoides. Data regarding its use in PC-ALCL are limited to case reports and as the control arm of the ALCANZA trial where the response rate to bexarotene was low [
         <a href="#rid16">
          16,17
         </a>
         ]. Therefore, we reserve bexarotene for patients who have a contraindication to
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         or have failed methotrexate due to disease progression or toxicity. Bexarotene must be used with caution in patients with hypertriglyceridemia, liver dysfunction, or risk factors for pancreatitis.
        </p>
        <p>
         Although the package insert suggests a higher starting dose, we usually start at very low doses (ie, 225 mg total daily dose) with titration based on tolerance and response. In most circumstances we do not exceed 300 mg/m
         <sup>
          2
         </sup>
         daily, but doses as high as 400 mg/m
         <sup>
          2
         </sup>
         may be used in rare circumstances. Liver function, serum lipid levels, thyroid function (serum free T4), and complete blood counts should be monitored in each patient during treatment [
         <a href="#rid20">
          20,21
         </a>
         ]. Given the high incidence of hyperlipidemia with
         <a class="drug drug_general" data-topicid="8695" href="/z/d/drug information/8695.html" rel="external">
          bexarotene
         </a>
         , we prescribe concomitant
         <a class="drug drug_general" data-topicid="91482" href="/z/d/drug information/91482.html" rel="external">
          fenofibrate
         </a>
         . Additional lipid lowering agents are sometimes necessary.
         <a class="drug drug_general" data-topicid="8488" href="/z/d/drug information/8488.html" rel="external">
          Gemfibrozil
         </a>
         should
         <strong>
          not
         </strong>
         be used because co-administration results in increased serum levels of bexarotene. This agent also causes central hypothyroidism and thyroid replacement must be adjusted based upon free T4 and not TSH. Further detail regarding the administration and toxicities of systemic bexarotene is presented separately. (See
         <a class="medical medical_review" href="/z/d/html/4759.html" rel="external">
          "Treatment of advanced stage (IIB to IV) mycosis fungoides", section on 'Systemic retinoids'
         </a>
         .)
        </p>
        <p>
         Most toxicities are reversible after cessation of therapy. The most common adverse effects include weakness, myalgia, arthralgia, and headaches. Retinoids have potential hepatotoxic and hyperlipidemic effects, necessitating monitoring. Women of childbearing potential should use two reliable forms of contraception, including at least one nonhormonal form given the well-known teratogenic effects of retinoids.
        </p>
        <p class="headingAnchor" id="H1139694642">
         <span class="h4">
          Brentuximab vedotin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="16806" href="/z/d/drug information/16806.html" rel="external">
          Brentuximab vedotin
         </a>
         (BV) is an anti-CD30 monoclonal antibody conjugated with monomethyl auristatin E by a protease-cleavable linker that has activity in lymphomas that express CD30. BV is approved by the US Food and Drug Administration (FDA) for treatment of PC-ALCL after at least one prior systemic therapy [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         The typical starting dose is 1.8 mg/kg (to a maximum dose of 180 mg) given intravenously every three weeks; BV can be given indefinitely until intolerance or disease progression. Infusion reactions are uncommon, but anaphylaxis has been reported. Peripheral neuropathy is the most common dose-limiting toxicity [
         <a href="#rid23">
          23
         </a>
         ], and can be managed with dose reduction to 1.2 mg/kg or increasing the dosing interval. Progressive multifocal leukoencephalopathy is a rare complication of BV treatment and typically presents with subacute neurologic deficits, which may include altered mental status, visual symptoms, weakness, ataxia, and seizures. (See
         <a class="medical medical_review" href="/z/d/html/2811.html" rel="external">
          "Infusion-related reactions to therapeutic monoclonal antibodies used for cancer therapy", section on 'Brentuximab'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1694.html" rel="external">
          "Progressive multifocal leukoencephalopathy (PML): Epidemiology, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2825.html" rel="external">
          "Neurologic complications of cancer treatment with molecularly targeted and biologic agents", section on 'Brentuximab'
         </a>
         .)
        </p>
        <p>
         An international, open-label trial randomly assigned 128 patients with CD30-expressing PC-ALCL (31 patients) or mycosis fungoides to treatment with BV versus the physician's choice (PC) of
         <a class="drug drug_general" data-topicid="8695" href="/z/d/drug information/8695.html" rel="external">
          bexarotene
         </a>
         or
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         [
         <a href="#rid18">
          18
         </a>
         ]. BV resulted in complete resolution of skin involvement in 10 of 16 patients (63 percent) with PC-ALCL. Compared with PC, BV achieved superior rates of:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Overall response that lasted at least four months (ORR4) among patients with PC-ALCL – 75 versus 20 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Complete response (skin plus extracutaneous disease) among patients with PC-ALCL – 31 versus 7 percent
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Median progression-free survival (in all patients) – 17 versus 4 months
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptomatic relief (measured by Skindex-29 score, in all patients) – 28 versus 9
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         There were comparable rates of grade 3/4 adverse events, but higher rates of peripheral neuropathy (any grade) in patients treated with BV (67 versus 6 percent).
        </p>
        <p>
        </p>
        <p>
         Other reports describe activity of BV in the setting of relapsed/refractory CD30-expressing cutaneous T cell lymphoma [
         <a href="#rid24">
          24,25
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1939875821">
         <span class="h4">
          Interferon
         </span>
         <span class="headingEndMark">
          —
         </span>
         Interferons have been used off-label for the treatment of mycosis fungoides and Sézary syndrome for decades. Data regarding the use of systemic interferon in PC-ALCL are limited to case reports, usually in combination with other agents [
         <a href="#rid26">
          26,27
         </a>
         ]. Interferon alfa can be given intralesionally or subcutaneously for systemic absorption if there are numerous lesions. The usual starting dose is 3 million units three times weekly with titration up or down based upon tolerance and efficacy. Interferon can cause depression as well as liver function and thyroid abnormalities. As a result of interferon’s toxicity and somewhat cumbersome method of administration, we favor
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         and
         <a class="drug drug_general" data-topicid="8695" href="/z/d/drug information/8695.html" rel="external">
          bexarotene
         </a>
         and reserve interferon for patients who progress on or are intolerant of those medications.
        </p>
        <p>
         The use of interferon alfa in mycosis fungoides and Sézary syndrome is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4759.html" rel="external">
          "Treatment of advanced stage (IIB to IV) mycosis fungoides", section on 'Interferon'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16616.html" rel="external">
          "Treatment of Sézary syndrome", section on 'Interferons (IFN)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2809350332">
         <span class="h4">
          Other agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9536" href="/z/d/drug information/9536.html" rel="external">
          Romidepsin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9530" href="/z/d/drug information/9530.html" rel="external">
          pralatrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         , and liposomal
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         can be used as single agents, as they are for mycosis fungoides and Sézary syndrome [
         <a href="#rid8">
          8,28,29
         </a>
         ]. The use of these agents in mycosis fungoides and Sézary syndrome is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4759.html" rel="external">
          "Treatment of advanced stage (IIB to IV) mycosis fungoides", section on 'Single agent chemotherapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16616.html" rel="external">
          "Treatment of Sézary syndrome", section on 'Single-agent chemotherapy'
         </a>
         .)
        </p>
        <p>
         Multiagent chemotherapy, such as CHOP (
         <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">
          cyclophosphamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10045" href="/z/d/drug information/10045.html" rel="external">
          vincristine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ), has not proven superior to less aggressive strategies. In an analysis of 53 patients, multiagent chemotherapy resulted in a complete response rate of 92 percent, but 62 percent of patients relapsed at a median of four months [
         <a href="#rid8">
          8
         </a>
         ]. On a subset analysis of patients treated with CHOP, the complete response rate was 85 percent and 71 percent relapsed. We reserve multiagent chemotherapy for patients with widespread nodal or visceral involvement or patients who have failed numerous single agents and skin-directed therapy. (See
         <a class="local">
          'Widespread nodal or visceral involvement'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1188949751">
         <span class="h3">
          Widespread nodal or visceral involvement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Widespread nodal or visceral involvement are adverse prognostic features that are uncommon at presentation, but may occur in later phases of the illness when multiple skin-directed or less toxic systemic therapies have failed [
         <a href="#rid30">
          30,31
         </a>
         ]. Extensive limb disease (ELD) on the same limb and/or contiguous body areas may also be an adverse prognostic feature.
        </p>
        <p>
         Patients with widespread nodal or visceral involvement or ELD can be treated with single agent systemic chemotherapy. We generally treat widespread systemic disease with
         <a class="drug drug_general" data-topicid="16806" href="/z/d/drug information/16806.html" rel="external">
          brentuximab vedotin
         </a>
         , if it was not previously used and there is no contraindication (eg, peripheral neuropathy). As mentioned previously, aggressive combination chemotherapy with CHOP or similar regimens is not more efficacious than single agents and should be reserved for the rare, advanced cases in which multiple single agent systemic therapies have proven unsuccessful. (See
         <a class="local">
          'Choice of agent'
         </a>
         above.)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9536" href="/z/d/drug information/9536.html" rel="external">
          Romidepsin
         </a>
         [
         <a href="#rid32">
          32
         </a>
         ],
         <a class="drug drug_general" data-topicid="9530" href="/z/d/drug information/9530.html" rel="external">
          pralatrexate
         </a>
         [
         <a href="#rid33">
          33
         </a>
         ],
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         [
         <a href="#rid28">
          28
         </a>
         ],
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         [
         <a href="#rid29">
          29
         </a>
         ], and liposomal
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         are also used as single agents as they are for mycosis fungoides and Sézary syndrome. The use of these agents in mycosis fungoides and Sézary syndrome is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4759.html" rel="external">
          "Treatment of advanced stage (IIB to IV) mycosis fungoides", section on 'Single agent chemotherapy'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16616.html" rel="external">
          "Treatment of Sézary syndrome", section on 'Single-agent chemotherapy'
         </a>
         .)
        </p>
        <p>
         Allogeneic hematopoietic cell transplantation may be considered for patients with multiple relapses progressing on systemic therapy. Data regarding its use in PC-ALCL are sparse. The use of transplantation in mycosis fungoides and Sézary syndrome is discussed in more detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4759.html" rel="external">
          "Treatment of advanced stage (IIB to IV) mycosis fungoides", section on 'Hematopoietic cell transplantation'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16616.html" rel="external">
          "Treatment of Sézary syndrome", section on 'Hematopoietic stem cell transplantation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H690878009">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cases of PC-ALCL have an excellent prognosis with an estimated 10-year overall survival rate of 90 percent [
         <a href="#rid34">
          34
         </a>
         ]. Recurrences are common with an estimated five-year failure-free survival rate of 55 percent. Leg involvement portends a worse prognosis. Patients with disease on the leg have a five-year disease-specific survival of 76 percent compared with 96 percent for other locations. Surprisingly, pathologic involvement of local nodes alone does not seem to portend an adverse prognosis [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H802432055">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/122000.html" rel="external">
          "Society guideline links: Primary cutaneous lymphoma"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3458893344">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a primary cutaneous CD30-positive lymphoproliferative disorder. Most patients present in their sixth decade with slowly enlarging solitary or grouped nodules. The nodules typically ulcerate with time and, while up to half regress, they rarely completely resolve. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Clinical and pathologic features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Skin biopsy usually demonstrates a dense dermal infiltrate comprised of CD30-positive tumor cells that morphologically resemble those of systemic ALCL. Unlike systemic ALCL, PC-ALCL lack expression of anaplastic lymphoma kinase (ALK) and do not have gene rearrangements involving the
         <em>
          ALK
         </em>
         gene on chromosome 2p23. (See
         <a class="local">
          'Clinical and pathologic features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The diagnosis of PC-ALCL is based upon the presence of characteristic findings on skin biopsy specimens in conjunction with the clinical features found on presentation. All patients with a presumed diagnosis of PC-ALCL should undergo a staging assessment to confirm the absence of systemic disease. A clinical or radiographic suspicion of disseminated disease should be confirmed by biopsy. Involvement of regional lymph nodes does not necessarily indicate the presence of systemic disease. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The main entities that should be considered in the differential diagnosis are lymphomatoid papulosis, systemic ALCL, transformed mycosis fungoides, and reactive causes of CD30-positive lymphoid infiltrates. (See
         <a class="local">
          'Differential diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         PC-ALCL is an indolent disease and avoidance of overtreatment is important. Most patients present with isolated lesions that can be managed with complete surgical excision (with negative margins) or radiation. Using this approach, the majority of patients will achieve a complete remission, although most will recur and require subsequent therapy. (See
         <a class="local">
          'Initial management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The management of recurrent disease is largely dependent on the extent of disease. Many patients will experience serial relapses. The choice of therapy for relapsed disease is made based on the patient's prior treatment and the therapies' expected toxicities (see
         <a class="local">
          'Recurrent disease'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Many localized cutaneous recurrences can be managed with further surgery or radiation. Given the tendency for spontaneous regression, recurrent lesions can be observed if they are not bothersome to the patient. (See
         <a class="local">
          'Localized lesions'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         We offer systemic therapy to patients with more widespread disease and to patients who experience multiple recurrences and in whom repeated surgical excision and/or radiation could become excessively morbid. (See
         <a class="local">
          'Choice of agent'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients requiring systemic therapy, we suggest initial treatment with single agent oral
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         rather than other chemotherapy regimens (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). Methotrexate is convenient and has a reasonable response rate and favorable toxicity profile. We typically treat to best response and then decrease the frequency of methotrexate and continue as maintenance therapy for a maximum of three years. If lesions recur after treatment discontinuation, re-treatment with methotrexate can be considered. (See
         <a class="local">
          'Oral methotrexate'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <a class="drug drug_general" data-topicid="16806" href="/z/d/drug information/16806.html" rel="external">
          Brentuximab vedotin
         </a>
         is an acceptable alternative for initial systemic therapy in patients who have previously received radiation treatment. (See
         <a class="local">
          'Brentuximab vedotin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who have a contraindication to, progressed on, or discontinued
         <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">
          methotrexate
         </a>
         due to significant toxicity, we suggest
         <a class="drug drug_general" data-topicid="16806" href="/z/d/drug information/16806.html" rel="external">
          brentuximab vedotin
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). (See
         <a class="local">
          'Brentuximab vedotin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients in whom the preceding therapies are ineffective or not tolerated, we offer sequential single agent therapy with systemic
         <a class="drug drug_general" data-topicid="8695" href="/z/d/drug information/8695.html" rel="external">
          bexarotene
         </a>
         ,
         <a class="drug drug_general" data-topicid="9536" href="/z/d/drug information/9536.html" rel="external">
          romidepsin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9530" href="/z/d/drug information/9530.html" rel="external">
          pralatrexate
         </a>
         ,
         <a class="drug drug_general" data-topicid="8430" href="/z/d/drug information/8430.html" rel="external">
          etoposide
         </a>
         ,
         <a class="drug drug_general" data-topicid="8487" href="/z/d/drug information/8487.html" rel="external">
          gemcitabine
         </a>
         , liposomal
         <a class="drug drug_general" data-topicid="9391" href="/z/d/drug information/9391.html" rel="external">
          doxorubicin
         </a>
         , or interferon alfa. (See
         <a class="local">
          'Bexarotene'
         </a>
         above and
         <a class="local">
          'Brentuximab vedotin'
         </a>
         above and
         <a class="local">
          'Interferon'
         </a>
         above and
         <a class="local">
          'Other agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Combination chemotherapy and allogeneic hematopoietic cell transplantation should be reserved for very rare cases with disseminated disease no longer responding to the treatments listed above. (See
         <a class="local">
          'Widespread nodal or visceral involvement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most cases of PC-ALCL have an excellent prognosis with the vast majority (90 percent) alive at 10 years after diagnosis. Recurrences are common and over half of patients will relapse within five years. (See
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu JB, Blitzblau RC, Decker RH, et al. Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database. J Clin Oncol 2008; 26:1483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Booken N, Goerdt S, Klemke CD. Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma Registry. J Dtsch Dermatol Ges 2012; 10:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95:3653.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weaver J, Mahindra AK, Pohlman B, et al. Non-mycosis fungoides cutaneous T-cell lymphoma: reclassification according to the WHO-EORTC classification. J Cutan Pathol 2010; 37:516.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu HL, Hoppe RT, Kohler S, et al. CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. J Am Acad Dermatol 2003; 49:1049.
          </a>
         </li>
         <li class="breakAll">
          World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, Swerdlow SH, Campo E, Harris NL, et al. (Eds), IARC Press, Lyon 2008.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kempf W, Pfaltz K, Vermeer MH, et al. EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Blood 2011; 118:4024.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melchers RC, Willemze R, van de Loo M, et al. Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma. Am J Surg Pathol 2020; 44:776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DeCoteau JF, Butmarc JR, Kinney MC, Kadin ME. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996; 87:3437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yang S, Khera P, Wahlgren C, et al. Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of ALK-1 status: case reports and review of literature. Am J Clin Dermatol 2011; 12:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeBoeuf NR, McDermott S, Harris NL. Case records of the Massachusetts General Hospital. Case 5-2015. A 69-year-old woman with recurrent skin lesions after treatment for lymphoma. N Engl J Med 2015; 372:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu JB, McNiff JM, Lund MW, Wilson LD. Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy. Int J Radiat Oncol Biol Phys 2008; 70:1542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Didona B, Benucci R, Amerio P, et al. Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol 2004; 150:1198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ardigò M, Marulli GC, Cota C, et al. Bexarotene and interferon-alpha combination therapy in a patient affected by relapsing anaplastic large cell lymphoma with cutaneous involvement. J Drugs Dermatol 2007; 6:216.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliveira A, Fernandes I, Alves R, et al. Primary cutaneous CD30 positive anaplastic large cell lymphoma--report of a case treated with bexarotene. Leuk Res 2011; 35:e190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheehy O, Catherwood M, Pettengell R, Morris TC. Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis. Leuk Lymphoma 2009; 50:1389.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol 1996; 34:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schadt CR. Topical and oral bexarotene. Dermatol Ther 2013; 26:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scarisbrick JJ, Morris S, Azurdia R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 2013; 168:192.
          </a>
         </li>
         <li class="breakAll">
          https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125388s097lbl.pdf (Accessed on December 14, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol 2012; 30:2190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duvic M, Tetzlaff MT, Gangar P, et al. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis. J Clin Oncol 2015; 33:3759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim YH, Tavallaee M, Sundram U, et al. Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. J Clin Oncol 2015; 33:3750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           French LE, Shapiro M, Junkins-Hopkins JM, et al. Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy. J Am Acad Dermatol 2001; 45:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McGinnis KS, Junkins-Hopkins JM, Crawford G, et al. Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms. J Am Acad Dermatol 2004; 50:375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma 2006; 7:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rijlaarsdam JU, Huijgens PC, Beljaards RC, et al. Oral etoposide in the treatment of cutaneous large-cell lymphomas. A preliminary report of four cases. Br J Dermatol 1992; 127:524.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woo DK, Jones CR, Vanoli-Storz MN, et al. Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome. Arch Dermatol 2009; 145:667.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fernández-de-Misa R, Hernández-Machín B, Combalía A, et al. Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma. J Eur Acad Dermatol Venereol 2020; 34:762.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010; 28:4485.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Horwitz SM, Kim YH, Foss F, et al. Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. Blood 2012; 119:4115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood 2008; 111:5496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Benner MF, Willemze R. Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma. Arch Dermatol 2009; 145:1399.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 99486 Version 19.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18349400" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Analysis of primary CD30+ cutaneous lymphoproliferative disease and survival from the Surveillance, Epidemiology, and End Results database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22525148" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10845893" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20132421" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Non-mycosis fungoides cutaneous T-cell lymphoma: reclassification according to the WHO-EORTC classification.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14639383" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14639383" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21841159" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32412717" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical, Histologic, and Molecular Characteristics of Anaplastic Lymphoma Kinase-positive Primary Cutaneous Anaplastic Large Cell Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8605362" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21366363" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Cutaneous anaplastic large-cell lymphoma should be evaluated for systemic involvement regardless of ALK-1 status: case reports and review of literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25671258" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Case records of the Massachusetts General Hospital. Case 5-2015. A 69-year-old woman with recurrent skin lesions after treatment for lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18037577" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Treatment of primary cutaneous CD30+ anaplastic large-cell lymphoma with radiation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15214911" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17373182" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Bexarotene and interferon-alpha combination therapy in a patient affected by relapsing anaplastic large cell lymphoma with cutaneous involvement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21764128" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Primary cutaneous CD30 positive anaplastic large cell lymphoma--report of a case treated with bexarotene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19544141" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Sustained response of primary cutaneous CD30 positive anaplastic large cell lymphoma to bexarotene and photopheresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Brentuximab vedotin or physician’s choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8609262" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24099070" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Topical and oral bexarotene.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22963233" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22963233" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22614995" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26261247" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26195720" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11712039" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Regression of multifocal, skin-restricted, CD30-positive large T-cell lymphoma with interferon alfa and bexarotene therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14988678" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16879770" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1467294" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Oral etoposide in the treatment of cutaneous large-cell lymphomas. A preliminary report of four cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19528422" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31591786" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20697094" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22394596" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18385450" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20026848" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Applicability and prognostic value of the new TNM classification system in 135 patients with primary cutaneous anaplastic large cell lymphoma.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
